Jpmorgan Chase & CO Fennec Pharmaceuticals Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Fennec Pharmaceuticals Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 10,505 shares of FENC stock, worth $55,886. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,505
Previous 10,314
1.85%
Holding current value
$55,886
Previous $63,000
17.46%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding FENC
# of Institutions
64Shares Held
14.9MCall Options Held
10KPut Options Held
83.8K-
Southpoint Capital Advisors LP New York, NY4.08MShares$21.7 Million0.57% of portfolio
-
Sonic Gp LLC Honolulu, HI2.41MShares$12.8 Million27.51% of portfolio
-
Solas Capital Management, LLC Darien, CT1.92MShares$10.2 Million7.68% of portfolio
-
Dg Capital Management, LLC New York, NY1.52MShares$8.1 Million4.41% of portfolio
-
Black Rock Inc. New York, NY1.19MShares$6.32 Million0.0% of portfolio
About FENNEC PHARMACEUTICALS INC.
- Ticker FENC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,067,300
- Market Cap $139M
- Description
- Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...